FBIO - Fortress Biotech Inc

FBIO - Fortress Biotech Inc

https://www.fortressbiotech.com

Recent News

Powered by Alpha Vantage

Journey Medical Corporation to Participate in September 2025 Investor Conferences

GlobeNewswire • 1 week, 5 days ago • score: 0.29

SCOTTSDALE, Ariz., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation ( "Journey Medical" or "the Company" ) ( Nasdaq: DERM ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ( "FDA" ) -approved prescription ...

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Fortress Biotech ( NASDAQ:FBIO ) , Fortress Biotech ( NASDAQ:FBIOP )

Benzinga • 1 week, 6 days ago • score: 0.41

MIAMI, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc. FBIO ( "Fortress" ) , an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today ...

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Business Insider • 1 week, 6 days ago • score: 0.36

MIAMI, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc. ( Nasdaq: FBIO ) ( "Fortress" ) , an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty ...

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 6 days ago • score: 0.36

MIAMI, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Fortress Biotech, Inc. ( Nasdaq: FBIO ) ( "Fortress" ) , an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty ...

Fortress Biotech ( FBIO ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.07

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -48.39% and +13.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.

52W High

$3.72

52W Low

$1.33

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.62

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.29

EV/Revenue (<3 favorable)

1.77

P/S (TTM) (<3 favorable)

1.86

P/B (<3 favorable)

2.51

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

20.98%

Institutions (25–75% balanced)

16.67%

Shares Outstanding

29,754,800

Float

22,175,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

59,301,000

Gross Profit (TTM)

8,975,000

EPS (TTM)

-0.91

Profit Margin (>10% good)

-0.25%

Operating Margin (TTM) (higher better)

-2.22%

ROE (TTM) (>15% strong)

-7.84%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.10

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—